Search
Ketotifen
go.drugbank.com/drugs/DB00920ApprovedInvestigationalavailable and indicated as an add-on therapy for children with atopic asthma. … [A231204] Ketotifen was first developed in Switzerland in 1970 by Sandoz Pharmaceuticals and was initially marketed for the treatment of anaphylaxis.
Products: PMS-ketotifen, KETOTIFENE EGAzelastine
go.drugbank.com/drugs/DB00972ApprovedInvestigationalAzelastine, a phthalazine derivative, is an antihistamine available as an intranasal spray for the treatment of allergic and vasomotor rhinitis and as an ophthalmic solution for the treatment of allergic … [L8240,L8270] It is a racemic mixture, though there is no noted difference in pharmacologic activity between enantiomers, and was first granted FDA approval in 1996.
Mixtures: N-S-4Products: Azelastin POS 1 mg/ml Nasenspray, LösungEdoxaban
go.drugbank.com/drugs/DB09075ApprovedInvestigationalIn addition to once daily dosing, the benefits over warfarin also include significant reductions in hemorrhagic stroke and GI bleeding, and improved compliance, which is beneficial as many patients will … This has prompted enthusiasm for newer agents such as dabigatran, apixaban, and rivaroxaban for effective clot prevention.
Products: PMS-edoxabanSumatriptan
go.drugbank.com/drugs/DB00669ApprovedInvestigational[A179761] Sumatriptan was granted FDA approval on 28 December 1992.[L6805] … [L6793,L6796,L6799,L6805,L6808,L6811] Sumatriptan is the first of the triptans and was made available in Europe in 1991 to treat migraines.
Synonyms: (3-[2-(dimethylamino)ethyl]-1H-indol-5-yl)-N-methylmethanesulfonamide, 3-[2-(dimethylamino)ethyl]-N-methylindole-5-methanesulfonamideProducts: PMS-sumatriptan, SUMATRIPTAN EGBezafibrate
go.drugbank.com/drugs/DB01393ApprovedInvestigationalAntilipemic agent that lowers cholesterol and triglycerides. It decreases low density lipoproteins and increases high density lipoproteins.
Products: PMS-bezafibrateCandesartan cilexetil
go.drugbank.com/drugs/DB00796ApprovedInvestigationalIt may also be used as an alternative agent for the treatment of heart failure, systolic dysfunction, myocardial infarction and coronary artery disease. … It is administered orally as the prodrug, candesartan cilexetil, which is rapidly converted to its active metabolite, candesartan, during absorption in the gastrointestinal tract.
Mixtures: PMS-candesartan-hctz, CANDESARTAN E IDROCLOROTIAZIDE EGCategories: Agents Acting on the Renin-Angiotensin SystemLidocaine
go.drugbank.com/drugs/DB00281ApprovedInvestigationalVet approvedEver since its discovery and availability for sale and use in the late 1940s, lidocaine has become an exceptionally commonly used medication [T583]. … Regardless, lidocaine is currently available as a relatively non-expensive generic medication that is written for in millions of prescriptions internationally on a yearly basis.
Mixtures: GPL Pak, LP Lite PAKSynonyms: 2-(Diethylamino)-N-(2,6-dimethylphenyl)acetamidePazopanib
go.drugbank.com/drugs/DB06589ApprovedInvestigationalIt is developed by GlaxoSmithKline and was FDA approved on October 19, 2009.
Products: PMS-pazopanibSorafenib
go.drugbank.com/drugs/DB00398ApprovedInvestigationalSorafenib is a bi-aryl urea and an oral multikinase inhibitor. … It targets cell surface tyrosine kinase receptors and downstream intracellular kinases that are implicated in tumour cell proliferation and tumour angiogenesis.
Synonyms: N-(4-Chloro-3-(trifluoromethyl)phenyl)-N'-(4-(2-(N-methylcarbamoyl)-4-pyridyloxy)phenyl)urea, 4-(4-((((4-Chloro-3-(trifluoromethyl)phenyl)amino)carbonyl)amino)phenoxy)-N-methyl-2-pyridinecarboxamideProducts: SORAFENIB EGTamsulosin
go.drugbank.com/drugs/DB00706ApprovedInvestigational[A178351] Tamsulosin was first approved by the FDA on April 15, 1997.[L6238] … [Label] Other alpha-1 adrenoceptor antagonists developed in the 1980s were less selective and more likely to act on the smooth muscle of blood vessels, resulting in hypotension.
Mixtures: DUTASTERIDE E TAMSULOSINA DOC, DUTASTERIDE E TAMSULOSINA DOCCategories: Drugs Used in Benign Prostatic Hypertrophy